Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia

Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability

“…Durrington et al (2001) found that omega-3 fatty acids (4 g) and simvastatin (10-40 mg) decreased serum triglyceride levels significantly more than treatment with simvastatin alone (À24 versus þ 11% at a 12-week follow-up, Po0.005). Maki et al (2008) reported that omega-3 fatty acids (4 g) plus simvastatin (20 mg) treatment for 6 weeks decreased triglyceride levels significantly more than treatment with a placebo plus simvastatin (À44 versus À29%) in mixed dyslipidemia patients. The combination of prescription omega-3 with simvastatin trial (Davidson et al, 2007) evaluated the efficacy of omega-3 fatty acids added to stable statin therapy in subjects with persistent hypertriglyceridemia.…”

Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: An Indian consensus statement

“…The physician's must rely on their own experience and knowledge to make diagnoses, to determine dosages and the best treatment for each individual patient and to take all appropriate safety precautions. 24 Sadovsky et al, 25 Maki et al, 26 Davidson et al, 27 Durrington et al 28 Fig . 2 e Risk ratio seen in various cardiovascular outcomes following supplementation with u-3 PUFA versus placebo.…”

“…Various researchers (Harris et al, 24 Sadovsky et al, 25 Maki et al, 26 Davidson et al, 27 Durrington et al 28 etc) have studied the effects of n-3 acid ethyl esters (90%) of EPA (460 mg) & DHA (380 mg) with or without statins in patients with hypertriglyceridemia. All have shown that n-3 acid ethyl esters (90%) of EPA (460 mg) & DHA (380 mg) was well tolerated and had a beneficial effect in terms of significant reduction in triglyceride levels (Fig.…”

Nutritional Management of Disturbances in Lipoprotein Concentrations

“…The hypotriglyceridaemic effect of long chain n-3 PUFAs, mediated by several mechanisms such as enhanced hepatic fatty acid oxidation [69], inhibition of fatty acid and triglyceride synthesis, reduced assembly and secretion of VLDL triglyceride concentrations [70], facilitates triglyceride rich lipoprotein removal through enhanced LPL activity in plasma [71]. Significant increases in HDL have been observed after DHA supplementation [67,68,72,73]; it may be related to decreased cholesteryl ester transfer protein activity that reduces the exchange from HDL cholesterol ester and VLDL, resulting in larger, more cholesterol-rich HDL cholesterol particles [74,75].…”